Drug-resistant epilepsy drug Ontozry backed by NICE
pharmaphorum
NOVEMBER 16, 2021
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The drug was eventually cleared in the EU in April, with the UK giving it a green light in June.
Let's personalize your content